Search Main Menu Main Content
  • Change contrast :
Retour à l'accueil du site de la HAS
logo HAS
icone
  • HAS profile
    • Mission
    • Organisational Structure
    • Ethics, transparency and management of conflicts of interest
  • International relations and projects
  • Publications
  1. Industriels
  2. Médicament
  3. TYSABRI (natalizumab)
  • icone plus
  • My account

    • Email alert Subscription
    • Newsletter Subscription
    • My search
    Refresh
    Please fill in your email address to retrieve your email alerts subscriptions.
    New subscription
    Please fill in your email address to retrieve your newsletter subscriptions.

    You do not have a saved search

    Mon Compte
  • No element in selection

    Favoris
  • Établissements de santé
  • Contact Abonnez-vous aux actualités
Listen Listen
Add to my selection
  • History
  • Technical informations
Share
Share on
Facebook share - facebook.com - new window
Tweeter share - Partager sur Twitter - twitter.com - new window
LinkedIn share - linkedin.com - new window
Print

TYSABRI (natalizumab)

Medicine - Posted on Nov 29 2021
Active substance (DCI)
  • natalizumab
history (5)
  • 9/8/21

    TYSABRI 150 mg (natalizumab)

    Mise à disposition d’une nouvelle présentation. Avis favorable au remboursement dans le traitement des formes très actives d...
    CAV :
    54321
    icône flèche
  • 10/3/18

    TYSABRI (-/ natalizumab/ natalizumab ((MAMMIFERE/SOURIS/CELLULES NSO)))

    TYSABRI (-/ natalizumab/ natalizumab ((MAMMIFERE/SOURIS/CELLULES NSO)))
    CAV :
    54321
    icône flèche
  • 6/21/17

    TYSABRI (-/ natalizumab/ natalizumab ((MAMMIFERE/SOURIS/CELLULES NSO)))

    Maintien du remboursement dans les mêmes conditions sous réserve d’une réévaluation de la stratégie thérapeutique. ...
    icône flèche
  • 2/29/12

    TYSABRI (-/ natalizumab/ natalizumab ((MAMMIFERE/SOURIS/CELLULES NSO)))

    TYSABRI (-/ natalizumab/ natalizumab ((MAMMIFERE/SOURIS/CELLULES NSO)))
    CAV :
    54321
    icône flèche
  • 1/17/07

    TYSABRI

    TYSABRI
    CAV :
    54321
    icône flèche
Technical information
ATC code
  • L04AA23
Manufacturer
BIOGEN FRANCE SAS
Presentation

TYSABRI 150 mg, solution injectable en seringue préremplie
Boite de 2 - (Code CIP : 34009 550 803 8 1)

TYSABRI 300 mg, solution à diluer pour perfusion (code CIS : 68722564)
1 flacon(s) en verre de 15 ml - (Code CIP : 34009 569 967 7 3)

All our publications
    Autoimmune diseases Central nervous system diseases Demyelinating diseases Drug therapy

Follow us :

  • Twitter (nouvelle fenêtre)
  • Facebook (nouvelle fenêtre)
  • Youtube (nouvelle fenêtre)
  • LinkedIn (nouvelle fenêtre)
Haute Autorité de Santé
Advancing quality in the fields of health and social care services
  • Eunetha.eu
  • Pasq.eu
  • All our publications by topic and type
  • Opinions on medicines
  • Opinions on medical devices
  • INAHTA briefs
  • Français
  • English
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
8cRHguYeDh3qR4Uq